Mutant KRAS codon 12 and 13 alleles in patients with metastatic colorectal cancer: Assessment as prognostic and predictive biomarkers of response to panitumumab

Journal of Clinical Oncology

Volumn 31, Issue 6, 2013, Pages 759-765

  Peeters, Marc ^a   Douillard, Jean Yves ^c   Van Cutsem, Eric ^b   Siena, Salvatore ^d   Zhang, Kathy ^e   Williams, Richard ^e   Wiezorek, Jeffrey ^e  

^a ANTWERP UNIVERSITY HOSPITAL   (Belgium)

^b UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^c UMR INSERM U892 CNRS 6299   (France)

^d OSPEDALE NIGUARDA CA GRANDA   (Italy)

^e AMGEN INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FLUOROURACIL; FOLINIC ACID; IRINOTECAN; K RAS PROTEIN; OXALIPLATIN; PANITUMUMAB;

ARTICLE; CANCER SURVIVAL; CODON; COLORECTAL CANCER; DRUG EFFICACY; HUMAN; METASTATIC COLORECTAL CANCER; OVERALL SURVIVAL; PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RETROSPECTIVE STUDY; TREATMENT RESPONSE;

ALLELES; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAMPTOTHECIN; CODON; COLORECTAL NEOPLASMS; DRUG RESISTANCE, NEOPLASM; FLUOROURACIL; GENE FREQUENCY; HUMANS; LEUCOVORIN; MUTATION; NEOPLASM METASTASIS; ORGANOPLATINUM COMPOUNDS; OUTCOME ASSESSMENT (HEALTH CARE); PROGNOSIS; PROTO-ONCOGENE PROTEINS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RAS PROTEINS; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 84875742535     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2012.45.1492     Document Type: Article

References (33)

1. Bardelli A, Siena S: Molecular mechanisms of resistance to cetuximab and panitumumab in colorectal cancer. J Clin Oncol 28:1254-1261, 2010
2. Siena S, Sartore-Bianchi A, Di Nicolantonio F, et al: Biomarkers predicting clinical outcome of epidermal growth factor receptor-targeted therapy in metastatic colorectal cancer. J Natl Cancer Inst 101:1308-1324, 2009
3. Roth AD, Tejpar S, Delorenzi M, et al: Prognostic role of KRAS and BRAF in stage II and III resected colon cancer: Results of the translational study on the PETACC-3, EORTC 40993, SAKK 60-00 trial. J Clin Oncol 28:466-474, 2010
4. Knijn N, Mekenkamp LJ, Klomp M, et al: KRAS mutation analysis: A comparison between primary tumours and matched liver metastases in 305 colorectal cancer patients. Br J Cancer 104:1020-1026, 2011
5. Santini D, Loupakis F, Vincenzi B, et al: High concordance of KRAS status between primary colorectal tumors and related metastatic sites: Implications for clinical practice. Oncologist 13:1270-1275, 2008
6. Douillard JY, Siena S, Cassidy J, et al: Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: The PRIME study. J Clin Oncol 28:4697-4705, 2010
7. Peeters M, Price TJ, Cervantes A, et al: Randomized phase III study of panitumumab with fluorouracil, leucovorin, and irinotecan (FOLFIRI) compared with FOLFIRI alone as second-line treatment in patients with metastatic colorectal cancer. J Clin Oncol 28:4706-4713, 2010
8. Van Cutsem E, Peeters M, Siena S, et al: Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer. J Clin Oncol 25:1658-1664, 2007 (Pubitemid 46797944)
9. Amado RG, Wolf M, Peeters M, et al: Wildtype KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol 26:1626-1634, 2008
10. Khambata-Ford S, Garrett CR, Meropol NJ, et al: Expression of epiregulin and amphiregulin and K-ras mutation status predict disease control in metastatic colorectal cancer patients treated with cetuximab. J Clin Oncol 25:3230-3237, 2007 (Pubitemid 47325606)
11. Van Cutsem E, Kohne CH, Hitre E, et al: Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med 360:1408-1417, 2009
12. De Roock W, Jonker DJ, Di Nicolantonio F, et al: Association of KRAS p.G13D mutation with outcome in patients with chemotherapy-refractory metastatic colorectal cancer treated with cetuximab. JAMA 304:1812-1820, 2010
13. Tejpar S, Celik I, Schlichting M, et al: Association of KRAS G13D tumor mutations with outcome in patients with metastatic colorectal cancer treated with first-line chemotherapy with or without cetuximab. J Clin Oncol 30:3570-3577, 2012
14. Gail M, Simon R: Testing for qualitative interactions between treatment effects and patient subsets. Biometrics 41:361-372, 1985
15. Deschoolmeester V, Boeckx C, Baay M, et al: KRAS mutation detection and prognostic potential in sporadic colorectal cancer using high-resolution melting analysis. Br J Cancer 103:1627-1636, 2010
16. Neumann J, Zeindl-Eberhart E, Kirchner T, et al: Frequency and type of KRAS mutations in routine diagnostic analysis of metastatic colorectal cancer. Pathol Res Pract 205:858-862, 2009
17. Andreyev HJ, Norman AR, Cunningham D, et al: Kirsten ras mutations in patients with colorectal cancer: The 'RASCAL II' study. Br J Cancer 85:692- 696, 2001 (Pubitemid 32929467)
18. Sundstrom M, Edlund K, Lindell M, et al: KRAS analysis in colorectal carcinoma: Analytical aspects of pyrosequencing and allele-specific PCR in clinical practice. BMC Cancer 10:660, 2010
19. Forbes SA, Bindal N, Bamford S, et al: COSMIC: Mining complete cancer genomes in the Catalogue of Somatic Mutations in Cancer. Nucleic Acids Res 39:D945-D950, 2011
20. Guerrero S, Casanova I, Farré L, et al: K-ras codon 12 mutation induces higher level of resistance to apoptosis and predisposition to anchorageindependent growth than codon 13 mutation or proto-oncogene overexpression. Cancer Res 60: 6750-6756, 2000
21. Guerrero S, Figueras A, Casanova I, et al: Codon 12 and codon 13 mutations at the K-ras gene induce different soft tissue sarcoma types in nude mice. FASEB J 16:1642-1644, 2002
22. Smith G, Bounds R, Wolf H, et al: Activating K-Ras mutations outwith 'hotspot' codons in sporadic colorectal tumours: Implications for personalised cancer medicine. Br J Cancer 102:693-703, 2010
23. Cé spedes MV, Sancho FJ, Guerrero S, et al: K-ras Asp12 mutant neither interacts with Raf, nor signals through Erk and is less tumorigenic than K-ras Val12. Carcinogenesis 27:2190-2200, 2006 (Pubitemid 44644807)
24. Deschoolmeester V, Baay M, Specenier P, et al: A review of the most promising biomarkers in colorectal cancer: One step closer to targeted therapy. Oncologist 15:699-731, 2010
25. Locker GY, Hamilton S, Harris J, et al: ASCO 2006 update of recommendations for the use of tumor markers in gastrointestinal cancer. J Clin Oncol 24:5313-5327, 2006 (Pubitemid 46631379)
26. Klump B, Nehls O, Okech T, et al: Molecular lesions in colorectal cancer: Impact on prognosisOriginal data and review of the literature. Int J Colorectal Dis 19:23-42, 2004 (Pubitemid 38088282)
27. Russo A, Bazan V, Agnese V, et al: Prognostic and predictive factors in colorectal cancer: Kirsten Ras in CRC (RASCAL) and TP53CRC collaborative studies. Ann Oncol 16:iv44-iv49, 2005 (Pubitemid 43084945)
28. Samowitz WS, Curtin K, Schaffer D, et al: Relationship of Ki-ras mutations in colon cancers to tumor location, stage, and survival: A populationbased study. Cancer Epidemiol Biomarkers Prev 9:1193-1197, 2000
29. De Roock W, De Vriendt V, Normanno N, et al: KRAS, BRAF, PIK3CA, and PTEN mutations: Implications for targeted therapies in metastatic colorectal cancer. Lancet Oncol 12:594-603, 2011
30. Orlandi A, Di Salvatore M, Basso M, et al: ERCC1, KRAS mutation, and oxaliplatin sensitivity in colorectal cancer: Old dogs and new tricks. J Clin Oncol 30, 2012 (suppl 4; abstr 489)
31. Gajate P, Sastre J, Bando I, et al: Influence of KRAS p.G13D mutation in patients with metastatic colorectal cancer treated with cetuximab. Clin Colorectal Cancer 11:291-296, 2012
32. Freeman D, Sun J, Bass R, et al: Panitumumab and cetuximab epitope mapping and in vitro activity. J Clin Oncol 15s:630s, 2008 (suppl; abstr 14536)
33. Montagut C, Dalmases A, Bellosillo B, et al: Identification of a mutation in the extracellular domain of the epidermal growth factor receptor conferring cetuximab resistance in colorectal cancer. Nat Med 18:221-223, 2012